# A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension

> **NCT00635232** · PHASE2 · COMPLETED · sponsor: **Ligand Pharmaceuticals** · enrollment: 261 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** irbesartan
- **DRUG:** placebo
- **DRUG:** PS433540
- **DRUG:** PS433540
- **DRUG:** PS433540

## Key facts

- **NCT ID:** NCT00635232
- **Lead sponsor:** Ligand Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2008-11
- **Final completion:** 2008-12
- **Target enrollment:** 261 (ACTUAL)
- **Last updated:** 2011-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00635232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00635232, "A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00635232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*